GlassScriptPhysician profile
Roberto M Nieto
NPI 1750430419
$245,943.34
in general payments reported to CMS, 2019-2025
77 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $47K · 2021: $44K · 2022: $34K · 2023: $19K · 2024: $3,068 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $11K · Travel and Lodging: $1,744 · Consulting Fee: $1,250 · Education: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $17,350.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,374.00 |
| Food and Beverage | $10,813.34 |
| Travel and Lodging | $1,744.18 |
| Consulting Fee | $1,250.00 |
| Education | $422.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $85,727.09 | 2019-2025 | Mavenclad |
| Amgen INC. | $39,232.99 | 2019-2025 | Uplizna, Aimovig |
| Allergan, INC. | $25,586.33 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $17,465.96 | 2019-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $15,657.78 | 2019-2025 | Qelbree |
| Axsome Therapeutics, INC. | $12,709.27 | 2023-2025 | Symbravo, Sunosi |
| Abbvie INC. | $11,268.09 | 2019-2025 | |
| Impel Pharmaceuticals INC. | $9,267.29 | 2022 | |
| Sk Life Science, INC. | $7,333.63 | 2020-2025 | Xcopri |
| Biohaven Pharmaceuticals, INC. | $3,412.45 | 2021 | |
| Pfizer INC. | $1,792.68 | 2019-2025 | |
| Biogen, INC. | $1,603.07 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Upsher-Smith Laboratories LLC | $1,576.79 | 2020-2023 | |
| Kyowa Kirin, INC. | $1,506.47 | 2019-2024 | Nourianz |
| Ucb, INC. | $1,460.01 | 2019-2025 | Fintepla, Briviact, Rystiggo |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $893.27 | 2019-2025 | Xywav |
| Neurocrine Biosciences, INC. | $765.72 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $574.90 | 2019-2025 | |
| Lundbeck LLC | $516.75 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $461.25 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Genzyme Corporation | $450.38 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $355.78 | 2019-2025 | Crexont, Rytary, Brekiya |
| Genentech USA, INC. | $332.18 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Sunovion Pharmaceuticals INC. | $295.40 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $278.35 | 2022-2025 | Quviviq, Quviviq |
| Currax Pharmaceuticals LLC | $263.30 | 2020-2025 | Onzetra Xsail |
| Arbor Pharmaceuticals, INC. | $261.88 | 2019-2022 | |
| Tg Therapeutics, INC. | $261.35 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $243.87 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $243.42 | 2022 | |
| Harmony Biosciences LLC | $242.02 | 2020-2024 | Wakix |
| Avanir Pharmaceuticals, INC. | $226.46 | 2019-2022 | |
| Mdd US Operations, LLC | $223.04 | 2021-2025 | Gocovri, Gocovri |
| Merck Sharp & Dohme LLC | $222.69 | 2019-2023 | Belsomra |
| Otsuka America Pharmaceutical, INC. | $190.36 | 2023-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $182.39 | 2024-2025 | Ponvory |
| Acadia Pharmaceuticals INC | $169.59 | 2019-2025 | Nuplazid |
| Almatica Pharma LLC | $160.68 | 2021-2022 | |
| Acorda Therapeutics, INC | $150.58 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $145.51 | 2024-2025 | Lumryz |
| Inspire Medical Systems, INC. | $144.75 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $129.08 | 2019-2025 | Trintellix |
| Argenx US, INC. | $125.35 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $123.18 | 2020-2025 | Zeposia |
| Impel Pharmaceuticals LLC | $120.48 | 2024-2025 | Trudhesa |
| Ipsen Biopharmaceuticals, INC | $108.29 | 2021 | |
| 3b Medical, INC. | $92.40 | 2023 | Luna |
| Banner Life Sciences, LLC | $85.73 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $85.23 | 2022-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $81.47 | 2021 | |
| Neurelis, INC. | $81.39 | 2021-2025 | Valtoco |
| Corium, LLC | $78.91 | 2022-2023 | Adlarity |
| Tanabe Pharma America, INC. | $78.28 | 2019-2024 | |
| Adamas Pharmaceuticals, INC. | $70.05 | 2019-2021 | |
| Validus Pharmaceuticals LLC | $69.86 | 2019 | |
| Abbott Laboratories | $65.73 | 2023 | Infinity |
| Janssen Pharmaceuticals, INC | $64.00 | 2022 | |
| Boston Scientific Corporation | $61.90 | 2025 | General - Dbs, Wavewriter Alpha Prime 16 |
| Aucta Pharmaceuticals, INC. | $54.60 | 2024 | Motpoly Xr |
| Grifols USA, LLC | $53.69 | 2024-2025 | Gamunex-C |
| Catalyst Pharmaceuticals, INC. | $50.16 | 2024 | |
| Zyla Life Sciences, INC. | $45.12 | 2020 | |
| Mallinckrodt Enterprises LLC | $42.05 | 2019 | |
| Promius Pharma LLC | $36.96 | 2019 | |
| Vertical Pharmaceuticals, LLC | $32.52 | 2020 | |
| Azurity Pharmaceuticals, INC. | $31.40 | 2024-2025 | |
| Assertio Therapeutics, INC. | $29.44 | 2019-2020 | |
| Janssen Biotech, INC. | $28.46 | 2025 | |
| Springworks Therapeutics, INC. | $27.76 | 2024 | |
| Merz Pharmaceuticals, LLC | $22.32 | 2024 | Xeomin |
| Scilex Pharmaceuticals INC. | $21.32 | 2024 | |
| Tonix Medicines, INC. | $21.15 | 2025 | Zembrace Symtouch |
| Medtronic, INC. | $20.03 | 2023 | Percept PC Brainsense |
| Medtronic USA, INC. | $17.21 | 2019 | |
| Ge Healthcare | $16.93 | 2024 | |
| Horizon Therapeutics Plc | $15.12 | 2023 | Uplizna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Nieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.